Cooper Companies Inc

Cooper Companies Inc(COO)股票分析

$70.090

-1.065 (-1.52%)收盘时

Loading chart…
High
70.755
Open
70.490
VWAP
70.16
Vol
2.16M
Mkt Cap
17.45B
Low
69.637
Amount
151.32M
EV/EBITDA, TTM
63.52

The Cooper Companies, Inc. is a medical device company. The Company's segments include CooperVision and CooperSurgical. The CooperVision segment is engaged in developing, manufacturing and marketing a broad range of products for contact lens wearers, featuring advanced materials and optics. Its daily disposable silicone hydrogel contact lens products include MyDay daily disposable, MyDay daily disposable toric, MyDay daily disposable multifocal, and MyDay Energys. The CooperSurgical segment provides a portfolio of products and services, including fertility products and services, medical devices, cryostorage (such as cord blood and cord tissue storage) and contraception. Its brands include ALLY II UPS, Advincula Delineator, Apple-Hunt Secondary Cannula, Bakri Postpartum Balloon, California Cryobank, Carter-Thomason, Cell Care, Cells for Life, Coda, Cord Blood Registry, Core Cryolab, Donor Egg Bank USA, ER-Complete, Embryo Options, and Endosee.

AI analysis of Cooper Companies Inc (COO)

hold

Currently, Cooper Companies Inc (COO) is not a strong buy. The stock is priced at $71.17, which is below the average analyst price target of $76. This indicates potential upside, but the stock has a low RSI of 20.795, suggesting it is oversold. However, the company has recently reported a significant decline in net income, with a net loss of $77.9 million in Q2 2026, which raises concerns about its financial health. The main risk is the projected sales growth slowing to 4.2% over the next 12 months, which is below the healthcare sector average.

Analyst Ratings (15)

+28.88% upside
Buy
10 Buy
5 Hold
0 Sell
Current: 70.09
最低
73.00
平均
90.33
最高
100.00

Citi

2026-08-13

目标价

$80

Neutral

UBS

2026-07-28

目标价

$75

Neutral

Citi

2026-07-08

目标价

$76

Neutral

Needham

2026-06-05

目标价

$86

Buy

JPMorgan

2026-06-05

目标价

$71

Neutral

估值指标

The current forward P/E ratio for Cooper Companies Inc (COO) is 14.45, compared to its 5-year average forward P/E of 23.33.

Forward P/E

Undervalued
5Y Average P/E
23.33
Current P/E
14.45
高估
28.32
低估
18.34

Forward EV/EBITDA

Strongly Overvalued
5Y Average EV/EBITDA
20.37
Current EV/EBITDA
63.52
高估
35.53
低估
5.22

Forward P/S

Undervalued
5Y Average P/S
4.49
Current P/S
3.07
高估
5.47
低估
3.51

Alphio AI Price Scenarios for COO

Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.

B

Bull

Bull · 25%COO

$100.88

情景价格

B

Base

Base · 50%COO

$92.29

情景价格

B

Bear

Bear · 25%COO

$83.71

情景价格

Whales holding COO

L

Longview Partners (Guernsey) Limited

+ HoldingCOO

+8.25%

3M Return

D

Diamond Hill Capital Management, Inc.

+ HoldingCOO

+5.01%

3M Return

H

Heartland Advisors, Inc.

+ HoldingCOO

+3.29%

3M Return

S

Staley Capital Advisers, Inc.

+ HoldingCOO

+1.74%

3M Return

M

Manning & Napier Advisors, LLC

+ HoldingCOO

+1.73%

3M Return

T

The London Company of Virginia, LLC

+ HoldingCOO

+0.90%

3M Return

事件时间线

2026-06-05 (ET)

16:30:00

Nasdaq Plummets Nearly 4% as Semiconductor Stocks Weaken

12:10:00

Cooper Companies Stock Rises 7.5% to $66.70

12:10:00

Major U.S. Stocks Broadly Lower at Noon, Semiconductor and AI Stocks Under Pressure

10:10:00

Cooper Companies Stock Rises 6.9% to $66.27

10:00:00

Cooper Companies Stock Rises $4.01 to $66.03

资讯

COO FAQ — answered by Alphio AI

The Cooper Companies, Inc. is a medical device company. The Company's segments include CooperVision and CooperSurgical. The CooperVision segment is engaged in developing, manufacturing and marketing a broad range of products for contact lens wearers, featuring advanced materials and optics. Its daily disposable silicone hydrogel contact lens products include MyDay daily disposable, MyDay daily disposable toric, MyDay daily disposable multifocal, and MyDay Energys. The CooperSurgical segment provides a portfolio of products and services, including fertility products and services, medical devices, cryostorage (such as cord blood and cord tissue storage) and contraception. Its brands include ALLY II UPS, Advincula Delineator, Apple-Hunt Secondary Cannula, Bakri Postpartum Balloon, California Cryobank, Carter-Thomason, Cell Care, Cells for Life, Coda, Cord Blood Registry, Core Cryolab, Donor Egg Bank USA, ER-Complete, Embryo Options, and Endosee. It operates in the Healthcare sector (OPHTHALMIC GOODS industry).

Currently, Cooper Companies Inc (COO) is not a strong buy. The stock is priced at $71.17, which is below the average analyst price target of $76. This indicates potential upside, but the stock has a low RSI of 20.795, suggesting it is oversold. However, the company has recently reported a significant decline in net income, with a net loss of $77.9 million in Q2 2026, which raises concerns about its financial health. The main risk is the projected sales growth slowing to 4.2% over the next 12 months, which is below the healthcare sector average.

15 analysts cover COO: 10 rate it Buy, 5 Hold and 0 Sell. The average price target is 90.33.

本页仅供研究参考,不构成投资建议。模型可能出错。过往表现不代表未来结果。

免费开始